| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1b data readout example | Phase 1b | — | Subscribe to access the data. | Small Molecules | Respiratory System | ||
Phase 1b data readout example | Phase 1b | — | Subscribe to access the data. | Small Molecules | Respiratory System | ||
Phase 1b data readout example | Phase 1b | — | Subscribe to access the data. | Small Molecules | Respiratory System |
Recent Updates
Recently added Catalysts
AgomAb Therapeutics NV$14.79
+1.27 (+9.36%)
D 31Pipeline Score Overvalued Biotech · Clinical
Market Cap
560.47 M
EPS
-
P/E Ratio
-
Value Trade
1.08 M
4.26 %
Week
4.03 %
1 Month
-25.81 %
3 Month
-20.96 %
6 Month
-20.96 %
5 Year
-20.96 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
38.24 K
52 Week Range
9 - 17.45
% held by Insiders
25.59 %
% held by Institutions
22.45 %
Enterprise Value
425.11 M
Total Shares
48.74 M
Short %
3.42 %
Float Shares
36.13 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
D31
Pipeline Score $217M
Pipeline ValueOvervalued
Valuation Signal4
Drugs Scored0.4x
rNPV / MCap Top 39%
Micro Cap (rank 564 of 923)
Percentile RankAgomAb Therapeutics NV faces pipeline headwinds (31/100), with $831M risk-adjusted pipeline value, led by AGMB-129 in Fibrostenotic Crohn's Disease (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AGMB-129 Small molecule | Fibrostenotic Crohn's Disease | Phase 2 | NCT07118878 | 16% | $346M | COMPLETED | 133 | - | - | Sep 15, 2025 | - | Nov 21, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in AGMB
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
AGMB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
AGMB▲ +6.2%on this news· ran to +49% by day 3
Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease
Agomab Therapeutics has announced the design of its Phase 2b NOV-ERA study for ontunisertib, aimed at treating Fibrostenosing Crohn's Disease. The study has received regulatory alignment from the FDA on key design elements, including a novel primary endpoint. The company expects to begin dosing participants in the second half of 2026.
Read more →AGMB▲ +5.6%on this news
Agomab Announces Results of Annual General Meeting
Agomab Therapeutics NV announced the successful outcomes of its Annual General Meeting held on May 26, 2026. All agenda items, including the approval of financial statements and reappointments of board members, were approved. The company continues to focus on developing therapies for fibro-inflammatory diseases.
Read more →AGMBAgomab to Participate in Upcoming Conferences
Agomab Therapeutics NV has announced its participation in several upcoming industry and investor conferences. Key presentations will include a poster on AGMB-447, which targets idiopathic pulmonary fibrosis, and fireside chats at major investor events. These engagements aim to showcase Agomab's advancements in fibro-inflammation treatments.
Read more →AGMBAgomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook -- Cash and Cash Investments at
Agomab Therapeutics NV has reported its financial results for the year ending December 31, 2025, showing an operating loss of $59.3 million and a net loss of $62.5 million. The company raised $208 million through its IPO, which is expected to extend its cash runway into the first half of 2029. Progress in clinical trials was noted, with positive FDA interactions and plans to initiate Phase 2 studies for Ontunisertib and AGMB-447 in 2026. The company remains focused on achieving key clinical milestones and advancing its innovative therapies for fibro-inflammatory diseases.
Read more →AGMBAgomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook
Agomab Therapeutics NV has reported its financial results for the year ending December 31, 2025, highlighting a solid cash position of €116.5 million. The company also confirmed its positive outlook for 2026, indicating confidence in its future operations and strategic direction. This announcement reflects Agomab's commitment to addressing fibro-inflammation.
Read more →AGMB▼ -7.7%on this news· ran to -18% by day 3
Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis
Agomab Therapeutics has been granted a U.S. patent for AGMB-447, an inhaled small molecule inhibitor aimed at treating Idiopathic Pulmonary Fibrosis (IPF). This patent secures intellectual property rights for AGMB-447 until at least 2041. The drug is currently undergoing a Phase 1b study, with results expected later this year. Agomab emphasizes the potential of AGMB-447 to meet significant medical needs in IPF.
Read more →AGMBAgomab Announces Closing of Initial Public Offering
Agomab Therapeutics NV has successfully closed its initial public offering, raising approximately $200 million by offering 12.5 million American Depositary Shares at $16.00 each. The shares began trading on the Nasdaq Global Select Market under the ticker AGMB on February 6, 2026. The company is focused on developing therapies for chronic fibrotic diseases, addressing significant unmet medical needs.
Read more →AGMBAgomab Announces Pricing of Initial Public Offering
Agomab Therapeutics NV has announced the pricing of its initial public offering, aiming to raise $200 million by offering 12.5 million American Depositary Shares at $16.00 each. The shares are set to begin trading on the Nasdaq Global Select Market on February 6, 2026. The offering is expected to close on February 9, 2026, pending customary conditions.
Read more →AGMBAgomab Announces Launch of Initial Public Offering
Agomab Therapeutics NV has announced the launch of an initial public offering (IPO) of 12,500,000 American Depositary Shares (ADSs), each representing one common share. The expected price range for the ADSs is between $15.00 and $17.00, and the company anticipates granting underwriters the option to purchase an additional 1,875,000 ADSs. Agomab, focused on developing novel therapies for chronic fibrotic diseases, has applied for listing on the Nasdaq Global Select Market under the ticker symbol 'AGMB'.
Read more →AGMBAgomab Announces Positive Phase 1 Interim Results with AGMB-447 in Healthy Participants and Initiation of Idiopathic Pulmonary Fibrosis Cohort
Agomab Therapeutics has reported positive interim results from its Phase 1 study of AGMB-447, an inhaled small molecule inhibitor targeting ALK5 for the treatment of Idiopathic Pulmonary Fibrosis. The study involved healthy participants and marks a significant step in Agomab's clinical development. The company is now initiating a cohort specifically for Idiopathic Pulmonary Fibrosis.
Read more →AGMBAgomab Announces Positive Topline Phase 2a Data for Ontunisertib in Fibrostenosing Crohn’s Disease
Agomab Therapeutics has reported positive topline results from its Phase 2a clinical trial of ontunisertib, an oral small molecule inhibitor targeting ALK5, for treating Fibrostenosing Crohn's Disease. The trial involved 103 participants who completed 12 weeks of treatment, indicating potential efficacy in this challenging condition.
Read more →AGMBLate-Breaking Interim STENOVA Data for AGMB-129 in Fibrostenosing Crohn’s to be Presented at Digestive Disease Week® 2025
Agomab Therapeutics announced that interim data from the STENOVA1 Phase 2a clinical trial of AGMB-129 will be presented at Digestive Disease Week 2025. AGMB-129 is an oral small molecule inhibitor targeting ALK5 for Fibrostenosing Crohn's Disease. The presentation is scheduled for May 3-6, 2025, in San Diego.
Read more →AGMBAgomab Announces Positive Topline Phase 2a Interim Results for AGMB-129 in Fibrostenosing Crohn’s Disease
Agomab has announced positive interim results from its Phase 2a trial of AGMB-129 for fibrostenosing Crohn's disease. The treatment successfully met all primary and secondary endpoints after 12 weeks in a study involving 44 patients. Detailed results will be shared at an upcoming scientific conference, with full results expected in Q4 2025.
Read more →AGMBAgomab Announces the Appointment of Former Sandoz CFO Colin Bond to its Board of Directors
Agomab Therapeutics has appointed Colin Bond as a non-executive Director and Chairman of the Audit Committee. Bond brings over 30 years of finance experience, including 15 years as CFO at various biopharmaceutical companies. His extensive background is expected to strengthen Agomab's financial oversight and strategic direction.
Read more →AGMBAgomab Announces $89 Million Series D Financing to Support Broad Fibrosis- focused Pipeline
Agomab Therapeutics has secured $89 million in Series D financing to enhance its fibrosis-focused pipeline. The funding will support the ongoing clinical development of AGMB-129 for fibrostenosing Crohn's disease and AGMB-447 for idiopathic pulmonary fibrosis. Interim data from the Phase 2a STENOVA trial is anticipated in early 2025.
Read more →AGMBAgomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer
Agomab Therapeutics has appointed Pierre Kemula as its new Chief Financial Officer, effective November 1, 2024. Kemula, who has over 15 years of experience in biotech finance, previously served as CFO at CureVac, where he successfully led significant capital raises. He succeeds Tolga Hassan, who has left the company for new opportunities.
Read more →AGMBAgomab Appoints Industry Veteran David Epstein as Chairman of its Board of Directors
Agomab Therapeutics has appointed David Epstein as the new Chairman of its Board of Directors. Epstein, a seasoned industry leader, previously served as CEO of Seagen, where he oversaw substantial growth and a major acquisition by Pfizer. With over 30 years of experience in drug development and commercialization, he is recognized as a significant figure in biopharma.
Read more →AGMBAgomab Receives FDA Orphan Drug Designation for AGMB-447 in Idiopathic Pulmonary Fibrosis
Agomab Therapeutics has received Orphan Drug Designation from the FDA for AGMB-447, an inhaled small molecule inhibitor aimed at treating Idiopathic Pulmonary Fibrosis (IPF). This designation supports the development of AGMB-447, which is currently being evaluated in a Phase 1 clinical trial. The designation provides Agomab with various benefits, including market exclusivity and financial incentives.
Read more →AGMBAgomab Starts Phase 1 Clinical Study for AGMB-447 in Healthy Subjects and Patients with Idiopathic Pulmonary Fibrosis
Agomab Therapeutics has commenced a Phase 1 clinical study for AGMB-447, an inhaled small molecule inhibitor targeting ALK5. The trial will assess the drug's safety and efficacy in both healthy individuals and patients suffering from idiopathic pulmonary fibrosis. This marks a significant step in developing new therapies for lung conditions.
Read more →AGMBAgomab Appoints Angelika Jahreis as Member of the Board of Directors and Andrea Sáez as Chief Development Officer
Agomab Therapeutics has appointed Angelika Jahreis as an independent non-executive director and Andrea Sáez as Chief Development Officer. These appointments are part of the company's growth strategy, with founders Paolo Michieli and Torsten Dreier transitioning to advisory roles. This move aims to enhance Agomab's leadership as it develops programs for fibrotic diseases.
Read more →AGMBAgomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline
Agomab Therapeutics NV has successfully closed a $100 million Series C financing round. The funding was led by Fidelity Management & Research Company and included participation from new investors such as EQT Life Sciences and Canaan. This capital will be utilized to advance Agomab's pipeline focused on fibrosis.
Read more →AGMBAgomab Receives FDA Fast Track Designation for AGMB-129 in Fibrostenosing Crohn’s Disease and Starts STENOVA Phase 2a Clinical Trial
Agomab Therapeutics has announced that it has received Fast Track Designation from the FDA for its drug AGMB-129, aimed at treating Fibrostenosing Crohn's Disease. Additionally, the company has commenced the STENOVA Phase 2a clinical trial to evaluate the efficacy of AGMB-129. This designation may expedite the development process for the treatment.
Read more →Competitive Position
How AGMB ranks across every disease it competes inCompetitive Position is a premium feature
See how AGMB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial